$BCEL News
Last published 2y ago
- 2y agoBCELIMNMImmunome to Acquire Antibody-Related Assets and Materials from AtrecaBusiness WireImmunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with
- 2y agoBCELIMNMAtreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to ImmunomeGlobeNewswireCAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. ("Atreca") (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on
- 2y agoBCELAtreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic AlternativesGlobeNewswireSAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform
- 3y agoBCELAtreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb CrossGlobeNewswireSAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform
- 3y agoBCELAtreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual MeetingGlobeNewswireClinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated Phase 2 go/no-go decisions for ATRC-101
- 3y agoBCELAtreca Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewswireSAN CARLOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform
- 3y agoBCELAtreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual MeetingGlobeNewswireSAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through a unique discovery
- 3y agoBCELAtreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceGlobeNewswireSAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform
- 3y agoBCELAtreca, Inc. (BCEL) Q4 2022 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoBCELAtreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data UpdateGlobeNewswireATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go
- 3y agoBCELAtreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023GlobeNewswireSAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform
- 3y agoBCELAtreca to Participate at Cowen's 43rd Annual Health Care ConferenceGlobeNewswireSAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform
- 3y agoBCELXNCRAtreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor TargetGlobeNewswireSAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a
- 3y agoBCELAtreca Appoints Philippe Bishop, MD as Chief Medical OfficerGlobeNewswireSAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform
- 4y agoBCELAtreca Reports Third Quarter 2022 Financial Results and Provides Pipeline UpdateGlobeNewswireSAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel
- 4y agoBCELAtreca to Present at Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform
- 4y agoBCELAtreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireSAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 4y agoBCELAtreca to Present at Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the acti
- 4y agoBCELAtreca Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewswireSAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 4y agoBCELAtreca to Present at Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 4y agoBCELCellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business OfficerBusiness Wire- Industry Veterans Expand Company's Business and Operations Functions Cellino Biotech, Inc., an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abh
- 4y agoBCELAtreca Appoints Stephen Gould, Ph.D. as Chief Scientific OfficerGlobeNewswireSAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 4y agoBCELAtreca Announces Corporate Reorganization to Extend Cash RunwayGlobeNewswireCompany continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets Extends cash runway through 2023 and reduces workforce by more than 25% On track to report data from ATRC-101 and ATRC-301 programs in 2H2022 SAN CARLOS, Calif.,
- 4y agoBCELAtreca to Present at Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active
- 4y agoBCELAtreca Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewswireSAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active
- 4y agoBCELAtreca Announces Publication in PNAS: "Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101"GlobeNewswireSAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active
- 4y agoBCELAtreca to Present at Upcoming Virtual Investor ConferencesGlobeNewswireSAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the acti
- 4y agoBCELZYMEAtreca Announces Expansion of Preclinical PipelineGlobeNewswireAtreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (
- 4y agoBCELAtreca to Host Virtual R&D Day on Tuesday, April 5, 2022GlobeNewswireSAN CARLOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the acti
- 4y agoBCELCLVSEOSEMARA+1Thinking about buying stock in Eos Energy Enterprises, Norwegian Cruise Line, Marathon Digital, Clovis Oncology, or Atreca?PR NewswireNEW YORK, March 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EOSE, NCLH, MARA, CLVS, and BCEL.
- 4y agoBCELAtreca to Participate in Cowen 42nd Annual Healthcare ConferenceGlobeNewswireSAN CARLOS, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the acti
- 4y agoBCELAtreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data UpdateGlobeNewswirePartial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial Clinical activity observed in multiple tumor types and significantly
- 4y agoBCELAtreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022GlobeNewswireSAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 4y agoBCELAtreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as DrugsGlobeNewswireSAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 5y agoBCELAtreca to Present at Upcoming Virtual Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 5y agoBCELAtreca Reports Third Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewswireSAN CARLOS, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 5y agoBCELAtreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of MalariaGlobeNewswireSAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 5y agoBCELAtreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireSAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 5y agoBCELAtreca to Present at Upcoming Virtual Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the acti
- 5y agoBCELAtreca Reports Second Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewswireSAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 5y agoBCELAtreca to Present at Upcoming Virtual Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 5y agoBCELAtreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid TumorsGlobeNewswireCompleted dose escalation portion of Phase 1b trial; ATRC-101 was well-tolerated with no dose-limiting toxicities observed Disease control associated with ATRC-101 target expression; preliminary biomarker data support the proposed mechanism of action
- 5y agoBCELAtreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101GlobeNewswireSAN CARLOS, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the activ
- 5y agoBCELAtreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of DirectorsGlobeNewswireSAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active
- 5y agoBCELAtreca to Present at Upcoming Virtual Investor ConferencesGlobeNewswireSAN CARLOS, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune r
- 5y agoBCELAtreca Reports First Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewswireSAN CARLOS Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active
- 5y agoBCELAtreca to Present at Upcoming Virtual Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery...
- 5y agoBCELAtreca Announces Poster Presentation at the Virtual American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated...
- 5y agoBCELAtreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate DevelopmentsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through...
- 5y agoBCELAtreca to Participate at Upcoming Virtual Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through...